Follow along in the GLP-1 BLUEPRINT workbook
Additionally, patients with certain gastrointestinal issues, such as past pancreatitis, may not be ideal candidates
Satiety is not just feeling full but feeling satisfied, says Ruder
Proponents of legal access to peptides, including Kennedy, argue that restricting them only drives Americans deeper into the grey market
This is the third installment as a part of an overarching $27 billion investment Eli Lilly announced earlier this February to build four US-based manufacturing sites
Renal impairment GLP-1 RAs are generally safe in patients with CKD and have demonstrated nephroprotective effects in the FLOW trial, where semaglutide significantly reduced the composite renal endpoint (hospitalization for acute kidney injury, sustained 50% decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death) in patients with type 2 diabetes and CKD [15]